develop
countri
vaccin
manufactur
network
dcvmn
gather
leader
immun
program
vaccin
manufactur
repres
argentinean
health
author
pan
american
health
organ
among
global
health
stakehold
annual
gener
meet
bueno
air
reflect
vaccin
shape
global
health
polio
erad
elimin
measl
rubella
america
result
success
collabor
made
possibl
time
suppli
afford
vaccin
decad
intens
competit
highvalu
market
collabor
develop
countri
becom
critic
involv
multipl
manufactur
well
publicand
privatesector
invest
essenti
develop
new
vaccin
emerg
infecti
diseas
recent
zika
viru
outbreak
acceler
ebola
vaccin
develop
exemplifi
need
intern
partnership
combat
infecti
diseas
new
player
coalit
epidem
prepared
innov
cepi
made
entranc
global
health
commun
aim
stimul
research
prepared
emerg
infect
facetofac
panel
discuss
facilit
dialogu
around
challeng
risk
viabil
vaccin
develop
regulatori
converg
improv
access
sustain
vaccin
suppli
discuss
joint
effort
optim
regulatori
pathway
develop
countri
reduc
registr
time
requir
outbreak
emerg
infect
global
polio
erad
contain
challeng
remind
import
vaccin
access
import
new
publicpriv
partnership
develop
countri
vaccin
manufactur
network
dcvmn
world
largest
vaccineindustri
allianc
corpor
member
work
provid
highqual
vaccin
contribut
global
health
initi
ensur
uninterrupt
vaccin
suppli
countri
advanc
erad
polio
facilit
respons
emerg
infecti
diseas
eid
outbreak
like
zika
outbreak
pharma
pakistan
hll
biotech
green
signal
bio
pharma
zydu
cadila
india
instituto
biologico
argentino
biol
argentina
member
emphas
import
collabor
partnership
among
member
achiev
sustain
suppli
highqual
afford
vaccin
accomplish
global
health
initi
one
initi
switch
trival
topv
bival
oral
polio
vaccin
bopv
eventu
inactiv
polio
vaccin
ipv
order
contain
poliovirus
better
ultim
erad
polio
j
lemu
minist
health
argentina
began
remind
vaccin
potabl
water
effect
way
reduc
morbid
mortal
global
role
ministri
health
protect
argentinian
popul
promot
healthi
live
outbreak
argentina
underscor
valu
local
vaccin
manufactur
also
emphas
import
support
intern
suppli
affirm
argentinian
govern
vaccin
manufactur
commit
work
paho
provid
highqual
vaccin
global
mp
kieni
review
evolv
collabor
innov
vaccin
develop
histor
one
scientist
like
edward
jenner
could
develop
vaccin
came
small
group
loui
pasteur
colleagu
innov
subsequ
becam
work
larg
team
sometim
span
sever
corpor
decad
intens
competit
highvalu
market
collabor
develop
countri
becom
critic
involv
multipl
manufactur
well
publicand
privatesector
invest
essenti
mening
project
malaria
vaccin
develop
illustr
effort
develop
vaccin
african
epidem
acceler
ebola
vaccin
develop
requir
urgent
collabor
manufactur
regulatori
author
fund
agenc
respond
contain
emerg
outbreak
follow
registr
first
dengu
vaccin
advanc
dengu
vaccin
collabor
butantan
nation
institut
health
nih
encourag
partnership
dcvm
publicsector
entiti
full
particip
dcvmn
member
futur
innov
collabor
requir
increas
develop
capabl
novel
product
process
regulatori
skill
along
equal
partnership
justifi
invest
nation
regulatori
agenc
nra
capabl
conclud
commit
public
health
joint
respons
essenti
h
sigman
chairman
group
insud
sinergium
welcom
meet
particip
introduc
sinergium
technolog
transfer
capabl
provid
exampl
partnership
public
privat
sector
confirm
import
collabor
among
vaccin
manufactur
director
paho
cf
etienn
present
via
video
paho
undertaken
make
nation
health
program
sustain
afford
encourag
improv
qualiti
avail
vaccin
privat
public
sector
rubella
elimin
america
region
first
region
declar
free
measl
thank
dcvmn
member
contribut
nation
immun
program
paho
commit
continu
collabor
dcvmn
member
welcom
innov
suggest
ensur
america
sustain
access
lifesav
vaccin
danel
deputi
director
paho
outlin
achiev
public
health
goal
america
includ
extens
reach
nation
immun
program
new
vaccin
introduct
strengthen
regulatori
pathway
improv
financ
forecast
mechan
elimin
measl
america
result
countri
work
togeth
success
made
possibl
time
suppli
measlesrubella
mr
measlesmumpsrubella
mmr
vaccin
dcvmn
member
dcvm
vaccin
repres
total
volum
million
dose
procur
paho
revolv
fund
paho
constantli
seek
altern
sourc
vaccin
adopt
strategi
enabl
manufactur
find
new
opportun
encourag
dcvmn
member
get
involv
fasttrack
develop
vaccin
enhanc
sustain
suppli
introduc
requir
vaccin
k
owen
bmgf
review
number
death
avert
immun
discuss
challeng
creat
stabl
vaccin
suppli
develop
countri
stabl
suppli
requir
highqual
manufactur
capac
commit
financ
strong
regulatori
system
predict
demand
bmgf
effort
focus
partner
manufactur
stimul
procur
optim
regulatori
pathway
develop
countri
reduc
registr
time
challeng
around
predict
remain
recent
exampl
challeng
transit
demand
opv
ipv
essenti
dcvm
strategi
sustain
busi
competit
market
r
bright
present
barda
role
tackl
emerg
reemerg
infecti
diseas
larg
number
potenti
eid
unpredict
emerg
requir
multihazard
strategi
invest
broad
spectrum
vaccin
platform
emerg
threat
requir
rapid
coordin
respons
integr
diagnost
earli
detect
therapeut
vaccin
collabor
multipl
group
develop
evalu
vaccin
new
suppli
fund
model
becom
increasingli
necessari
respond
effici
current
compani
develop
zika
vaccin
includ
dcvmn
member
bharat
butantan
sinergium
urg
dcvm
work
zika
candid
vaccin
meet
foster
possibl
partnership
f
kristensen
provid
overview
new
coalit
epidem
prepared
innov
cepi
cepi
aim
priorit
stimul
financ
coordin
advanc
vaccin
develop
eid
epidem
potenti
especi
market
incent
alon
achiev
ebola
respons
show
possibl
advanc
clinic
develop
vaccin
emerg
manufactur
capabl
capac
vaccin
bottleneck
crise
thu
effort
focu
drive
vaccin
manufactur
pipelin
also
fund
diagnost
therapeut
cepi
seek
multiyear
donor
contribut
one
billion
dollar
align
strateg
object
mission
oper
principl
equit
access
cost
coverag
share
risk
benefit
fund
cepi
avail
vaccin
produc
consortia
track
record
bring
vaccin
candid
human
clinic
trial
founder
cepi
govern
india
norway
bill
melinda
gate
foundat
wellcom
trust
world
econom
forum
wef
cepi
fact
launch
wef
meet
davo
januari
j
kalil
discuss
emerg
reemerg
diseas
tropic
region
butantan
develop
dengu
zika
vaccin
current
phase
iii
clinic
trial
show
result
compar
nih
vaccin
develop
zika
candid
vaccin
undertaken
urgent
respons
recent
outbreak
south
america
ideal
situat
would
develop
combin
vaccin
zika
dengu
butantan
will
collabor
compani
develop
zika
vaccin
test
candid
vaccin
endem
area
malham
review
gavi
strategi
inform
lesson
previou
period
includ
foster
innov
product
strengthen
collabor
though
engag
industri
clearer
inclus
criteria
vaccin
improv
consist
market
analysi
forecast
secur
multipl
vaccin
supplier
posit
impact
effect
immun
program
gavi
new
strategi
three
prioriti
take
longterm
view
market
help
countri
manufactur
prepar
transit
selffinanc
align
product
innov
prioriti
across
marketshap
partner
match
need
adopt
higher
toler
risk
market
requir
lastli
malham
extend
gavi
gratitud
dcvmn
member
contribut
suppli
vaccin
poor
countri
gavi
continu
shape
healthi
vaccin
suppli
global
rautio
note
total
unicef
procur
billion
dedic
vaccin
total
billion
dose
vaccin
procur
unicef
reach
world
children
dose
sourc
dcvm
total
valu
million
provid
import
market
opportun
dcvm
vaccin
secur
sustain
uninterrupt
suppli
afford
vaccin
assur
qualiti
achiev
accur
forecast
avail
fund
appropri
contract
divers
supplier
base
critic
therefor
continu
engag
dcvm
essenti
beyond
secur
expand
programm
immun
epi
vaccin
unicef
engag
suppli
pipelin
vaccin
outbreak
health
humanitarian
emerg
improv
access
afford
new
vaccin
middleincom
countri
mic
unicef
support
develop
healthi
market
leverag
procur
transpar
price
build
procur
capac
countri
pentaval
vaccin
exampl
market
consid
healthi
year
procur
first
dose
j
fitzsimmon
provid
overview
paho
technic
cooper
strategi
countri
america
includ
consider
nation
decisionmak
introduc
new
vaccin
nation
immun
program
paho
sustain
model
immun
consist
nation
vaccin
forecast
nation
budgetari
financ
legisl
revolv
fund
mechan
togeth
facilit
access
vaccin
four
decad
experi
model
proven
effect
america
enjoy
high
immun
coverag
tradit
new
vaccin
success
paho
revolv
fund
enabl
highlevel
commit
member
countri
busi
model
highqual
vaccin
suppli
dcvm
supplier
fig
panel
discuss
moder
j
chu
chai
focus
manag
decis
contribut
increas
success
greater
commerci
viabil
vaccin
vaccin
manufactur
critic
compon
global
health
come
risk
one
exampl
declin
success
rate
clinic
trial
pharmaceut
includ
vaccin
past
year
scientif
manag
factor
contribut
four
risk
categori
larg
potenti
returnhigh
feasibl
eg
innov
respiratori
syncyti
viru
rsv
group
b
streptococcu
gb
vaccin
small
potenti
return
high
feasibl
larg
market
opportun
low
feasibl
small
market
opportun
low
feasibl
fig
emphas
balanc
portfolio
critic
ensur
compani
remain
viabl
datla
said
increasingli
import
choos
vaccin
portfolio
wise
biolog
e
exampl
take
pride
support
epi
need
india
well
gavi
countri
also
followon
vaccin
limit
new
product
introduct
mani
compani
end
similar
pipelin
undercapac
capac
suppli
influenc
sustain
custom
manufactur
respect
pentaval
vaccin
prime
exampl
overcapac
demand
divid
among
larger
group
manufactur
reduct
market
share
challeng
manufactur
sustain
busi
model
depend
reason
market
share
mic
uniqu
characterist
size
birth
cohort
abil
procur
local
registr
requir
reluct
join
pool
procur
howev
seek
vaccin
gavi
price
pose
anoth
challeng
manufactur
sustain
highincom
countri
differ
barrier
entri
requir
heavi
invest
due
need
clinic
trial
access
fund
vaccin
develop
also
get
increasingli
difficult
take
year
vaccin
reach
market
investor
prefer
faster
higher
return
j
khalil
note
partnership
help
reduc
financi
risk
butantan
histori
forg
success
partnership
multin
compani
primari
object
domest
suppli
access
hpv
vaccin
possibl
local
govern
enabl
technolog
transfer
agreement
butantan
priorit
innov
product
product
valuabl
market
manufactur
capac
exce
demand
lower
price
would
possibl
malham
explain
gavi
assist
supplier
understand
competit
commerci
risk
involv
publish
strateg
demand
forecast
roadmap
analyz
countri
donor
select
product
compani
also
need
develop
strategi
gavi
also
analyz
cost
administr
calcul
weight
averag
price
vaccin
need
expand
convers
price
per
dose
cost
per
child
immun
rautio
comment
unicef
focu
secur
suppli
unicef
host
confer
vaccin
manufactur
annual
market
forecast
provid
unicef
work
close
ministri
health
variou
countri
estim
demand
supplier
howev
reli
unicef
similarli
market
reliant
one
supplier
j
fitzsimmon
comment
anoth
risk
manufactur
differ
product
requir
differ
market
gavi
paho
market
network
opportun
meet
offer
forum
discuss
issu
develop
common
target
product
profil
relev
across
publichealth
market
g
widmyer
acknowledg
bmgf
uniqu
posit
shape
global
health
financ
agenc
seek
lowest
price
supplier
need
support
vaccin
develop
bmgf
divers
portfolio
fund
project
variou
diseas
agenda
may
overlap
case
invest
manufactur
may
result
excess
capac
avail
gavi
market
addit
domest
market
compani
must
focu
financi
viabil
foundat
keen
engag
supplier
seek
invest
show
portfolio
reflect
strateg
balanc
vision
trust
transpar
interact
critic
jl
di
fabio
open
session
regulatori
converg
effort
facilit
registr
improv
access
health
product
p
aprea
director
biolog
evalu
control
nation
administr
medicin
food
technolog
argentina
anmat
remark
converg
current
biggest
challeng
regulatori
author
requir
confid
clariti
competit
must
appli
regulatori
decina
present
draft
good
regulatori
practic
grp
guidelin
nra
guidelin
intend
assist
regul
regul
organ
irrespect
resourc
level
provid
framework
improv
practic
principl
regulatori
system
establish
key
concept
impact
analysi
stakehold
consult
nine
major
principl
legal
imparti
consist
proportion
flexibl
effect
effici
clariti
transpar
import
share
inform
present
type
intern
regulatori
cooper
help
avoid
redund
regulatori
work
exampl
relianc
mutual
recognit
share
region
approach
regulatori
harmon
use
pan
american
drug
regulatori
harmon
pandrh
network
technic
cooper
approach
regulatori
system
strengthen
rss
america
encompass
three
work
stream
facilit
develop
contextspecif
nation
regulatori
system
promot
regulatori
converg
harmon
support
effici
use
resourc
leverag
work
other
program
reli
peerassess
nra
use
standard
indic
regulatori
capac
adopt
institut
develop
plan
base
identifi
gap
particip
impli
commit
undergo
assess
assess
result
share
particip
nra
aggreg
data
publish
onlin
region
platform
access
innov
health
technolog
prai
conclud
effort
repres
new
trend
toward
converg
regulatori
system
america
n
dellepian
discuss
manufactur
contribut
dialogu
global
regulatori
converg
review
exist
approach
regulatori
harmon
includ
relianc
within
regul
network
provis
mutual
support
align
requir
procedur
standard
among
regulatori
agenc
continu
relianc
mutual
recognit
nra
network
initi
improv
technic
scientif
expertis
joint
review
activ
partnership
nra
remain
import
align
nra
agre
follow
common
list
essenti
document
fulfil
countryspecif
requir
registr
file
may
also
foster
regulatori
converg
encourag
dcvmn
member
collect
data
relat
variou
registr
approach
contribut
dialogu
regulatori
group
industri
j
iyer
present
view
access
medicin
foundat
role
manufactur
promot
access
goal
gather
insight
pharmaceut
compani
improv
access
medicin
rank
corpor
base
criteria
research
develop
capac
afford
manufactur
suppli
access
vaccin
index
develop
help
understand
compani
make
vaccin
access
low
middleincom
countri
vaccin
manufactur
assess
monitor
track
progress
base
analysi
provid
index
benchmark
intern
busi
strategi
atherli
present
studi
path
center
vaccin
innov
access
dynam
vaccin
uptak
developingcountri
market
project
goal
acceler
develop
introduct
product
high
health
impact
path
collabor
dcvmn
member
chengdu
institut
biolog
product
cdibp
develop
introduct
japanes
enceph
je
vaccin
collabor
help
obtain
prequalif
first
whoprequalifi
vaccin
china
product
capac
increas
approxim
million
children
outsid
china
vaccin
cdibp
je
vaccin
envis
eight
addit
countri
introduc
je
vaccin
part
nation
immun
program
lim
chai
discuss
risk
potenti
futur
vaccin
market
advis
compani
understand
market
exist
competit
compar
select
candid
product
base
potenti
risk
return
result
optim
balanc
product
portfolio
respons
chang
vaccin
market
dynam
j
fourniercaruana
gave
updat
global
action
plan
contain
poliovirus
gapiii
contain
certif
scheme
cc
endors
strateg
advisori
group
expert
sage
octob
respect
erad
polioviru
global
endeavour
achiev
engag
stakehold
globallysynchron
switch
trival
type
opv
bival
opv
type
april
start
polioviru
contain
period
elimin
vaccinederiv
type
polioviru
infect
howev
delay
polioviru
product
facil
research
facil
repositori
demonstr
implement
gapiii
nation
author
contain
nac
certifi
contain
realiz
mani
countri
due
lack
nation
regulatori
framework
implement
contain
stakehold
support
nation
contain
certif
effort
unicef
role
endgam
outlin
ottosen
includ
secur
suppli
polio
vaccin
well
synchron
withdraw
topv
roll
bopv
decemb
march
million
dose
opv
topv
bopv
deliv
time
manner
plan
activ
toward
topv
cessat
howev
percept
risk
increas
among
supplier
programm
manag
industri
survey
emphas
necess
involv
supplier
earli
stage
decisionmak
final
opv
cessat
allow
integr
strategi
ensur
suffici
suppli
recent
polio
outbreak
nigeria
requir
million
vaccin
dose
dcvm
provid
larg
quantiti
flexibl
stockpil
respons
capac
due
shortag
ipv
unicef
current
abl
meet
recommend
least
one
ipv
dose
countri
therefor
octob
sage
recommend
fractionaldos
ipv
fipv
onefifth
normal
ipv
intramuscular
dose
deliv
intraderm
catchup
ipv
vaccin
becom
avail
current
countri
access
ipv
boyl
bmgf
elabor
ipv
use
challeng
rational
behind
switch
topv
bopv
sinc
indigen
transmiss
wild
polioviru
detect
compon
topv
make
vaccinederiv
poliovirus
caus
vaccineassoci
paralyt
polio
case
also
interfer
immun
respons
type
poliovirus
respons
shortag
ipv
recommend
two
dose
fipv
deliv
intraderm
week
along
routin
bopv
well
campaign
immun
ipv
suppli
constraint
expect
remain
issu
bmgf
prioriti
includ
reliabl
suppli
bopv
introduc
maintain
ipv
routin
immun
assess
potenti
new
mucosalimmun
enhanc
adjuv
genet
stabl
opv
b
giers
present
role
initi
vaccin
research
ivr
acceler
vaccin
develop
access
vaccin
lmic
challeng
around
new
vaccin
develop
includ
invest
driven
highincom
countri
lack
robust
regulatori
pathway
differ
health
prioriti
among
stakehold
sinc
pathogen
includ
rsv
evalu
ivr
ivr
also
evalu
new
deliveri
strategi
exampl
microarray
patch
map
administr
mr
vaccin
map
requir
minim
train
lightweight
thermost
yet
provid
effici
tradit
vaccin
ivr
wish
provid
neutral
evid
valu
new
technolog
overcom
challeng
vaccin
zehrung
review
new
vaccin
deliveri
technolog
includ
map
ipv
mr
blowfills
tube
rotaviru
integr
reconstitut
packag
intraderm
deliveri
technolog
new
deliveri
technolog
like
reduc
commod
system
cost
result
greater
access
health
impact
worldwid
zaffran
report
current
situat
global
polio
endgam
strategi
lowest
number
case
polio
report
case
pakistan
afghanistan
four
new
case
wildtyp
nigeria
event
caus
concern
restrict
access
conflict
zone
contribut
lack
surveil
access
vaccin
april
announc
switch
topv
bopv
remov
opv
end
august
countri
introduc
ipv
prioriti
next
six
month
interrupt
transmiss
three
endem
countri
maintain
activ
surveil
securityand
ipvdepriv
countri
contain
maintain
poliofre
statu
dcvmn
annual
gener
meet
provid
occas
profession
vaccin
industri
global
health
organ
discuss
challeng
innov
risk
gain
deeper
understand
regulatori
practic
converg
opportun
zika
outbreak
polio
endgam
remind
import
vaccin
also
import
collabor
collect
effort
global
partnership
dcvmn
aim
foster
network
opportun
support
member
shape
global
health
